Fusion Pharmaceuticalsinc Stock Buy Hold or Sell Recommendation
FUSN Stock | USD 21.42 0.10 0.47% |
Given the investment horizon of 90 days and your conservative risk appetite, our recommendation regarding Fusion PharmaceuticalsInc is 'Strong Sell'. Macroaxis provides Fusion PharmaceuticalsI buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding FUSN positions. The advice algorithm takes into account all of Fusion PharmaceuticalsI's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Fusion PharmaceuticalsI's buy or sell advice are summarized below:
Real Value 18.87 | Target Price 13.1 | Hype Value 21.52 | Market Value 21.42 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Fusion PharmaceuticalsInc given historical horizon and risk tolerance towards Fusion PharmaceuticalsI. When Macroaxis issues a 'buy' or 'sell' recommendation for Fusion PharmaceuticalsInc, the advice is generated through an automated system that utilizes algorithms and statistical models.
Fusion |
Execute Fusion PharmaceuticalsI Buy or Sell Advice
The Fusion recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Fusion PharmaceuticalsInc. Macroaxis does not own or have any residual interests in Fusion PharmaceuticalsInc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Fusion PharmaceuticalsI's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | OK | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Fusion PharmaceuticalsI Trading Alerts and Improvement Suggestions
Fusion PharmaceuticalsI is way too risky over 90 days horizon | |
Fusion PharmaceuticalsI appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 2.07 M. Net Loss for the year was (94.9 M) with loss before overhead, payroll, taxes, and interest of (57.43 M). | |
Fusion PharmaceuticalsInc currently holds about 198.42 M in cash with (81.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57. | |
Over 79.0% of the company shares are owned by institutional investors | |
Latest headline from zacks.com: Fusion Pharmaceuticals Inc. Stock Moves -0.09 percent What You Should Know |
Fusion PharmaceuticalsI Returns Distribution Density
The distribution of Fusion PharmaceuticalsI's historical returns is an attempt to chart the uncertainty of Fusion PharmaceuticalsI's future price movements. The chart of the probability distribution of Fusion PharmaceuticalsI daily returns describes the distribution of returns around its average expected value. We use Fusion PharmaceuticalsInc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Fusion PharmaceuticalsI returns is essential to provide solid investment advice for Fusion PharmaceuticalsI.
Mean Return | 1.84 | Value At Risk | -5.71 | Potential Upside | 6.69 | Standard Deviation | 12.66 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Fusion PharmaceuticalsI historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Fusion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fusion PharmaceuticalsI is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fusion PharmaceuticalsInc backward and forwards among themselves. Fusion PharmaceuticalsI's institutional investor refers to the entity that pools money to purchase Fusion PharmaceuticalsI's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Sphera Funds Management Ltd. | 2023-12-31 | 1.1 M | Artal Group S A | 2023-12-31 | 1 M | Blair William & Co | 2023-12-31 | 993.9 K | Wellington Management Company Llp | 2023-12-31 | 744.5 K | 1832 Asset Management L.p | 2023-12-31 | 734.3 K | Eagle Health Investments Lp | 2023-12-31 | 579.8 K | Millennium Management Llc | 2023-12-31 | 578.1 K | Ikarian Capital, Llc | 2023-12-31 | 500 K | Blackrock Inc | 2023-12-31 | 419.8 K | Federated Hermes Inc | 2023-12-31 | 10.9 M | Avidity Partners Management Lp | 2023-12-31 | 6.5 M |
Fusion PharmaceuticalsI Cash Flow Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Investments | (456K) | (210.5M) | 39.3M | 25.2M | (80.5M) | (76.4M) | |
Change In Cash | 38.0M | 25.3M | (37.6M) | (9.5M) | 17.6M | 18.5M | |
Free Cash Flow | (14.1M) | (30.9M) | (77.2M) | (75.4M) | (85.7M) | (81.4M) | |
Depreciation | 290K | 482K | 634K | 909K | 1.3M | 1.4M | |
Other Non Cash Items | (1.4M) | 39.6M | 11.7M | 2.1M | (222K) | (210.9K) | |
Net Income | (16.2M) | (78.3M) | (81.0M) | (87.6M) | (94.9M) | (90.2M) | |
End Period Cash Flow | 67.1M | 92.4M | 54.8M | 45.3M | 61.9M | 58.5M | |
Change To Netincome | (876K) | 42.3M | 16.5M | 9.1M | 10.5M | 12.6M |
Fusion PharmaceuticalsI Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Fusion PharmaceuticalsI or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Fusion PharmaceuticalsI's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Fusion stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 1.66 | |
β | Beta against NYSE Composite | 2.12 | |
σ | Overall volatility | 13.03 | |
Ir | Information ratio | 0.14 |
Fusion PharmaceuticalsI Volatility Alert
Fusion PharmaceuticalsInc is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Fusion PharmaceuticalsI's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Fusion PharmaceuticalsI's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Fusion PharmaceuticalsI Fundamentals Vs Peers
Comparing Fusion PharmaceuticalsI's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Fusion PharmaceuticalsI's direct or indirect competition across all of the common fundamentals between Fusion PharmaceuticalsI and the related equities. This way, we can detect undervalued stocks with similar characteristics as Fusion PharmaceuticalsI or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Fusion PharmaceuticalsI's fundamental indicators could also be used in its relative valuation, which is a method of valuing Fusion PharmaceuticalsI by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Fusion PharmaceuticalsI to competition |
Fundamentals | Fusion PharmaceuticalsI | Peer Average |
Return On Equity | -0.49 | -0.31 |
Return On Asset | -0.25 | -0.14 |
Operating Margin | (47.98) % | (5.51) % |
Current Valuation | 1.62 B | 16.62 B |
Shares Outstanding | 84.86 M | 571.82 M |
Shares Owned By Insiders | 4.39 % | 10.09 % |
Shares Owned By Institutions | 79.09 % | 39.21 % |
Number Of Shares Shorted | 5.2 M | 4.71 M |
Price To Book | 8.13 X | 9.51 X |
Price To Sales | 874.50 X | 11.42 X |
Revenue | 2.07 M | 9.43 B |
Gross Profit | (57.43 M) | 27.38 B |
EBITDA | (97.89 M) | 3.9 B |
Net Income | (94.9 M) | 570.98 M |
Cash And Equivalents | 198.42 M | 2.7 B |
Cash Per Share | 4.57 X | 5.01 X |
Total Debt | 50.33 M | 5.32 B |
Debt To Equity | 0.08 % | 48.70 % |
Current Ratio | 17.89 X | 2.16 X |
Book Value Per Share | 2.79 X | 1.93 K |
Cash Flow From Operations | (81.8 M) | 971.22 M |
Short Ratio | 1.35 X | 4.00 X |
Earnings Per Share | (1.45) X | 3.12 X |
Target Price | 21.67 | |
Number Of Employees | 101 | 18.84 K |
Beta | -0.72 | -0.15 |
Market Capitalization | 1.81 B | 19.03 B |
Total Asset | 285.84 M | 29.47 B |
Retained Earnings | (376.76 M) | 9.33 B |
Working Capital | 227.18 M | 1.48 B |
Net Asset | 285.84 M |
Note: Acquisition by Christopher Leamon of 106100 shares of Fusion PharmaceuticalsI at 8.44 subject to Rule 16b-3 [view details]
Fusion PharmaceuticalsI Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Fusion . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution | 14795.88 | |||
Daily Balance Of Power | 0.5882 | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 21.41 | |||
Day Typical Price | 21.41 | |||
Price Action Indicator | 0.065 | |||
Period Momentum Indicator | 0.1 |
About Fusion PharmaceuticalsI Buy or Sell Advice
When is the right time to buy or sell Fusion PharmaceuticalsInc? Buying financial instruments such as Fusion Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 7.6M | 10.0M | 9.9M | 7.3M | Total Assets | 252.3M | 219.1M | 285.8M | 214.3M |
Use Investing Ideas to Build Portfolios
In addition to having Fusion PharmaceuticalsI in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Thematic Idea Now
Obamacare
Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. The Obamacare theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Theme or any other thematic opportunities.
View All Next | Launch |
Check out Fusion PharmaceuticalsI Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Fusion Stock analysis
When running Fusion PharmaceuticalsI's price analysis, check to measure Fusion PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion PharmaceuticalsI is operating at the current time. Most of Fusion PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Fusion PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fusion PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Fusion PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Fusion PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion PharmaceuticalsI. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.032 | Quarterly Revenue Growth (1.00) | Return On Assets (0.25) | Return On Equity (0.49) |
The market value of Fusion PharmaceuticalsInc is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Fusion PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Fusion PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.